Written By: Ben Adams, Senior Editor, FierceBiotechhttps://www.fiercebiotech.com/biotech/rapha-capital-management-launches-100m-life-science-vc-fund-eye-early-science Life science venture capital firm Rapha Capital Management has launched its first managed venture capital fund with a target raise of $100M and…
– Rapha Capital BioVentures (RCBV) Fund, with a target of $100M, builds on Rapha Capital’s successful history guiding the advancements of target biotech investments – – RCBV Fund plans to…
Rapha Capital Management (RCM LLC) Joined by Mendham Investment Group (MIG FZ LLC) in Leading the Financing FIZE’s Novel iUO™ Device Conquers the Last Frontier in Patient Monitoring Rapha Capital’s…
NexImmune Raises Gross Proceeds of $126.5M in Upsized IPO Legacy SPIVs Establish Rapha Capital’s Expertise in Identifying Disruptive Technologies MIAMI, Feb. 24, 2021 /PRNewswire/ — Rapha Capital Management, LLC (https://raphacap.com), an investment…
Rapha Capital Management Leads Convertible Note Financing Miami, FL – February 8, 2021 – Ponce Therapeutics, Inc. (“Ponce”), a company leveraging the growing scientific knowledge surrounding the aging process to…
Asclepix Therapeutics, Inc. AsclepiX Therapeutics, Inc. Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for Diabetic Macular Edema (DME) January 5, 2021
NexImmune Inc. NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor Zeldis formerly served as Celgene CMO and CEO of Celgene…
NexImmune Inc. Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition Initial data demonstrate early signs of safety, tolerability and…
